# A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine

> **NCT05871541** · PHASE1 · COMPLETED · sponsor: **Immorna Biotherapeutics, Inc.** · enrollment: 75 (actual)

## Conditions studied

- Herpes Zoster (HZ)
- Shingles
- Infectious Disease

## Interventions

- **BIOLOGICAL:** JCXH-105
- **BIOLOGICAL:** Active Control (Shingrix)

## Key facts

- **NCT ID:** NCT05871541
- **Lead sponsor:** Immorna Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-26
- **Primary completion:** 2024-03-25
- **Final completion:** 2024-03-25
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05871541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05871541, "A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05871541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*